Cancers, Vol. 10, Pages 137: YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting

Cancers, Vol. 10, Pages 137: YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting

Cancers doi: 10.3390/cancers10050137

Authors: Federica Lo Sardo Sabrina Strano Giovanni Blandino

Lung cancer is the leading cause of cancer death in the world and there is no current treatment able to efficiently treat the disease as the tumor is often diagnosed at an advanced stage. Moreover, cancer cells are often resistant or acquire resistance to the treatment. Further knowledge of the mechanisms driving lung tumorigenesis, aggressiveness, metastasization, and resistance to treatments could provide new tools for detecting the disease at an earlier stage and for a better response to therapy. In this scenario, Yes Associated Protein (YAP) and Trascriptional Coactivator with PDZ-binding motif (TAZ), the final effectors of the Hippo signaling transduction pathway, are emerging as promising therapeutic targets. Here, we will discuss the most recent advances made in YAP and TAZ biology in lung cancer and, more importantly, on the newly discovered mechanisms of YAP and TAZ inhibition in lung cancer as well as their clinical implications.

https://ift.tt/2romhvc